Table 2a.
Switch rates and patterns among German patients with IBD who switched from biosimilar ABP 501 to another targeted therapy during the first 12 months after initiating ABP 501.
| Evaluated variable | All patients | ADA-naïve patients | ADA-experienced patients |
|---|---|---|---|
| All patients, n | 3362 | 1828 | 1534 |
| Total switched patients, n (%) | 763 (22.7) | 374 (20.5) | 389 (25.4) |
| Initial switching patterns post-ABP 501, n (%) | |||
| ADA reference product | 221 (29.0) | 38 (10.2) | 183 (47.0) a |
| ADA biosimilars (excluding ABP 501) | 126 (16.5) | 35 (9.4) | 91 (23.4) b |
| Non-ADA TNFi | 74 (9.7) | 57 (15.2) | 17 (4.4) |
| Non-TNFi biologics | 314 (41.2) | 220 (58.8) | 94 (24.2) |
| IL1 inhibitor | 1 (0.1) | 1 (0.3) | 0 (0.0) |
| IL12/23 inhibitor | 168 (22.0) | 110 (29.4) | 58 (14.9) |
| IL17 inhibitors | 2 (0.3) | 0 (0.0) | 2 (0.5) |
| IL6 inhibitors | 1 (0.1) | 0 (0.0) | 1 (0.3) |
| Integrin antagonists | 142 (18.6) | 109 (29.1) | 33 (8.5) |
| JAKi | 28 (3.7) | 24 (6.4) | 4 (1.0) |
ADA, adalimumab; IBD, inflammatory bowel disease; IL, interleukin; JAKi, Janus Kinase inhibitor; RP, reference product; TNFi, tumor necrosis factor inhibitor.
a
Included patients who were treated with RP (n = 165, 90.2%) or other ADA biosimilars (n = 18, 9.8%) prior to initiation of ABP 501.
b
Included patients who were treated with RP (n = 65, 71.4%) or other ADA biosimilars (n = 26, 28.6%) prior to initiation of ABP 501.